Back to Search
Start Over
CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
- Source :
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Publication Year :
- 2017
- Publisher :
- Lippincott Williams & Wilkins, 2017.
-
Abstract
- Supplemental Digital Content is available in the text.<br />Objective— Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis. In clinical trials, anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor, causes significant reductions in plasma Lp(a) levels. We conducted an exploratory study to examine the mechanism for Lp(a) lowering by anacetrapib. Approach and Results— We enrolled 39 participants in a fixed-sequence, double-blind study of the effects of anacetrapib on the metabolism of apoB and high-density lipoproteins. Twenty-nine patients were randomized to atorvastatin 20 mg/d, plus placebo for 4 weeks, and then atorvastatin plus anacetrapib (100 mg/d) for 8 weeks. The other 10 subjects were randomized to double placebo for 4 weeks followed by placebo plus anacetrapib for 8 weeks. We examined the mechanisms of Lp(a) lowering in a subset of 12 subjects having both Lp(a) levels >20 nmol/L and more than a 15% reduction in Lp(a) by the end of anacetrapib treatment. We performed stable isotope kinetic studies using 2H3-leucine at the end of each treatment to measure apo(a) fractional catabolic rate and production rate. Median baseline Lp(a) levels were 21.5 nmol/L (interquartile range, 9.9–108.1 nmol/L) in the complete cohort (39 subjects) and 52.9 nmol/L (interquartile range, 38.4–121.3 nmol/L) in the subset selected for kinetic studies. Anacetrapib treatment lowered Lp(a) by 34.1% (P≤0.001) and 39.6% in the complete and subset cohort, respectively. The decreases in Lp(a) levels were because of a 41% reduction in the apo(a) production rate, with no effects on apo(a) fractional catabolic rate. Conclusions— Anacetrapib reduces Lp(a) levels by decreasing its production. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00990808.
- Subjects :
- 0301 basic medicine
Male
Time Factors
Apolipoprotein B
Atorvastatin
030204 cardiovascular system & hematology
Severity of Illness Index
chemistry.chemical_compound
0302 clinical medicine
Interquartile range
Anacetrapib
Tandem Mass Spectrometry
cysteine
lipoprotein metabolism
Blood lipoproteins
biology
Chemistry
Anticholesteremic Agents
Lipoprotein(a)
Middle Aged
inhibitor
Treatment Outcome
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Medicine
lipids (amino acids, peptides, and proteins)
Female
Hypercholesteremia--Treatment
Cardiology and Cardiovascular Medicine
medicine.drug
ezetimibe
Adult
medicine.medical_specialty
Hypercholesterolemia
stable isotopes
Down-Regulation
Lipoproteins--Metabolism
Placebo
03 medical and health sciences
Double-Blind Method
Internal medicine
Cholesterylester transfer protein
CETP
medicine
Humans
Oxazolidinones
Aged
lipoprotein (a)
Pennsylvania
Cholesterol Ester Transfer Proteins
030104 developmental biology
Endocrinology
biology.protein
anacetrapib
New York City
Lipoprotein A
kringle
Biomarkers
Lipoprotein
Clinical and Population Studies
Chromatography, Liquid
Subjects
Details
- Language :
- English
- ISSN :
- 15244636 and 10795642
- Volume :
- 37
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Accession number :
- edsair.doi.dedup.....3f2ae6e707bffcfa7148a74b984400c9